The Drug Repurposing Hub: a next-generation drug library and information resource - PubMed (original) (raw)

. 2017 Apr 7;23(4):405-408.

doi: 10.1038/nm.4306.

Steven M Corsello 1 2 3, Zihan Liu 1, Joshua Gould 1, Patrick McCarren 1, Jodi E Hirschman 1, Stephen E Johnston 1, Anita Vrcic 1, Bang Wong 1, Mariya Khan 1, Jacob Asiedu 1, Rajiv Narayan 1, Christopher C Mader 1, Aravind Subramanian 1, Todd R Golub 1 3 4 5

Affiliations

The Drug Repurposing Hub: a next-generation drug library and information resource

Steven M Corsello et al. Nat Med. 2017.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing financial interests

The authors declare no competing financial interests.

Figures

Figure 1

Figure 1. The Repurposing Hub workflow for drug library creation

Drugs were identified, purchased, confirmed, and fully annotated. The final QC-confirmed library contains 1,988 drugs that are approved or marketed for clinical use around the world and 1,348 drugs that reached Phase 1–3 in clinical development.

Figure 2

Figure 2. Repurposing Library contents

A) Highest clinical phase achieved by each compound. 3,422 drugs in the Library have reached clinical use as of November 2016. B) Number of compounds per target category. Compounds with multiple targets may be indicated in more than one category. C) Number of approved drugs for indications within each listed disease area. D) Classification of proteins targeted by Library drugs. Protein function hierarchy is shown with increasing specificity of function corresponding to distance from the figure center. The relative area of each segment is proportional to the fraction of the Repurposing Library targeting each protein class. As expected, the Library is enriched in drugs targeting kinases, GPCRs, and ion channels.

Similar articles

Cited by

References

    1. Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534:314–316. - PubMed
    1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32:40–51. - PubMed
    1. Goldstein I, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397–1404. - PubMed
    1. Palumbo A, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008;111:3968–3977. - PubMed
    1. Lamb J, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313:1929–1935. - PubMed

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources